-
再生医療（AMED）
分担研究者：東北大学 加藤幸成（代表：京都大学 金子 新）
令和５年度〜令和７年度
課題名：GPC3 CAR 発現 iPS 細胞由来 ILC/NK 細胞の患者体内生存延長 と抗腫瘍
エフェクター機能向上を目指したリバーストランスレーショナル研究
東北大学ではこれまで、がん細胞に特異的な反応性を示すモノクローナル抗体の作製法（CasMab法）を用いることにより、ポドプラニンに対して、複数のCasMabの作製に成功した。ポドプラニンはリンパ管内皮細胞、肺胞上皮細胞、皮膚基底細胞、腎上皮細胞などの全身の正常細胞に高発現し、通常の抗体では様々な副作用が懸念される。CasMabはそれらの正常細胞に反応せず、肺がん、食道がん、悪性中皮腫、悪性脳腫瘍、卵巣がんなどの複数の難治性がんに高い反応性を示すため、抗体医薬の新規ターゲットとして期待される。さらに、乳がんや膵がんの他に血管内皮細胞などの正常細胞にも高発現しているポドカリキシンに対しても、がん特異的な反応性を示すCasMabを複数作製してきた。本プロジェクトにおいては、京都大学が保有するがん特異的抗体をヒト化あるいはscFv化し、CAR-Tに搭載できるフォーマットへの最適化を行う。
-
＜文献＞
25bm1123027h0001
2025
49. Yamamoto H, Suzuki H, Tanaka T, Satofuka H, Kaneko MK, Kato Y.
Development of a novel anti-mouse CCR7 monoclonal antibody C7Mab-2 by immunization of the extracellular loop domain
Microbes & Immunity, 3(1), 172–180; https://doi.org/10.36922/MI025130028, 2026 (PDF; preprint)
48. Ubukata R, Suzuki H, Kaneko MK, Kato Y.
Development of novel anti-CDH1/E-cadherin monoclonal antibodies for flow cytometry, western blotting, and immunohistochemistry
Biochem Biophys Rep, 45, 102401, https://www.sciencedirect.com/science/article/pii/S2405580825004881, 2026 (PDF; preprint)
47. Ohishi T, Suzuki H, Kaneko MK, Tanaka T, Harakawa A, Yoshida J, Tatsuda D, Kato Y, Kawada M.
Design and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer Therapy
Cancer Sci, 116(12):3417-3430, doi: 10.1111/cas.70198, 2025 (PDF; preprint)
46. Tanaka T, Yamamoto H, Kaneko Y, Shinoda K, Nakamura T, Li G, Fujisawa S, Satofuka H, Kaneko MK, Suzuki H, Kato Y.
Ea8Mab-9: a novel monoclonal antibody against erythropoietin-producing hepatocellular receptor A8 for flow cytometry
Microbes & Immunity, 2(4), 150–160; https://doi.org/10.36922/MI025060010, 2025 (PDF; preprint)
45. Okada A, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Analysis of an Anti-Mouse CCR1 Monoclonal Antibody S15040E Using Flow Cytometry
Biochem Biophys Rep, 44, 102265, https://doi.org/10.1016/j.bbrep.2025.102265, 2025 (PDF; preprint)
44. Ubukata R, Ohishi T, Kaneko MK, Suzuki H, Kato Y.
EphB2-targeting monoclonal antibodies exerted antitumor activities in triple-negative breast cancer and lung mesothelioma xenograft models.
Int. J. Mol. Sci., 26(17), 8302; https://doi.org/10.3390/ijms26178302, 2025 (PDF; preprint)
43. Suzuki H, Ohishi T, Nakamura T, Yanaka M, Handa S, Tanaka T, Kaneko MK, Kato Y.
A cancer-specific anti-podocalyxin monoclonal antibody (humPcMab-60) demonstrated antitumor efficacy against human cancer xenografts
antibodies, 14(3), 67; https://doi.org/10.3390/antib14030067, 2025 (PDF; preprint)
42. Ubukata R, Suzuki H, Hirose M, Satofuka H, Tanaka T, Kaneko MK, Kato Y.
Establishment of a highly-sensitive and specific anti-EphB2 monoclonal antibody Eb2Mab-12 for Flow Cytometry
Microbes & Immunity, 2(3), 168–177, https://doi.org/10.36922/mi.5728, 2025 (PDF; preprint)
41. Haruto Yamamoto, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato
PMab-322: a novel anti-hippopotamus podoplanin monoclonal antibody for multiple applications
Biochem Biophys Rep, 43, 102170, https://doi.org/10.1016/j.bbrep.2025.102170, 2025 (PDF; preprint)
40. Ubukata R, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of an anti-CDH15/M-cadherin monoclonal antibody Ca15Mab-1 for flow cytometry, western blotting, and immunohistochemistry
Biochem Biophys Rep, 43, 1021382025, https://doi.org/10.1016/j.bbrep.2025.102138, 2025 (PDF; preprint)
39. Kaneko Y, Tanaka T, Fujisawa S, Li G, Satofuka H, Kaneko MK, Suzuki H, Kato Y.
Development of a Novel Anti-Human Glypican 5 Monoclonal Antibody (G5Mab-1) for Multiple Applications
BBREP, 43, 102140, https://doi.org/10.1016/j.bbrep.2025.102140, 2025 (PDF; preprint)
38. Satofuka H, Suzuki H, Hirose M, Shinoda K, Nakamura T, Tanaka T, Kaneko MK, Kato Y.
Ea3Mab-20: A Specific Anti-Human EphA3 Monoclonal Antibody for Flow Cytometry
Biochem Biophys Rep, 43, 102130, https://www.sciencedirect.com/science/article/pii/S2405580825002171, 2025 (PDF; preprint)
37. Tanaka T, Suzuki H, Taruta H, Saga A, Li G, Fujisawa S, Kaneko MK, Kato Y.
Ea1Mab-30: a novel monoclonal antibody against erythropoietin-producing hepatocellular receptor A1 for versatile applications
Monoclon. Antib. Immunodiagn. Immunother., 44(3), 41-52, DOI: 10.1089/mab.2025.0006, 2025 (PDF; preprint)
36. Yamamoto H, Kaneko Y, Tanaka T, Li G, Suzuki H, Kaneko MK, Kato Y.
C8Mab-21: A Novel Anti-human CCR8 Monoclonal Antibody for Flow Cytometry
Microbes & Immunity, 2(2), 126–136, https://doi.org/10.36922/mi.4661, 2025 (PDF; preprint)
35. Satofuka H, Suzuki H, Tanaka T, Li G, Kaneko MK, Kato Y.
An Anti-Human EphA2 Monoclonal Antibody Ea2Mab-7 Shows High Sensitivity for Flow Cytometry, Western Blot, and Immunohistochemical Analyses
Biochem Biophys Rep, 42, 1019982024, 2025 (PDF; preprint)
34. Li G, Suzuki H, Tanaka T, Satofuka H, Kaneko MK, Kato Y.
A novel anti-mouse CXCR1 monoclonal antibody, Cx1Mab-8, demonstrates nanomolar affinity in flow cytometry
Biochem Biophys Rep, 42, 101965, 2025 (PDF; preprint)
33. Tanaka T, Kaneko Y, Yamamoto H, Li G, Fujisawa S, Satofuka H, Shinoda K, Nakamura T, Kaneko MK, Suzuki H, Kato Y.
Development of a novel anti-erythropoietin-producing hepatocellular receptor B6 monoclonal antibody Eb6Mab-3 for flow cytometry
Biochem Biophys Rep, 41, 101960, https://doi.org/10.1016/j.bbrep.2025.101960, 2024 (PDF; preprint)
32. Satofuka H, Suzuki H, Tanaka T, Ubukata R, Hirose M, Yamamoto H, Kaneko Y, Fujisawa S, Li G, Kaneko MK, Kato Y.
A novel Anti-Mouse CCR7 Monoclonal Antibody, C7Mab-7, Demonstrates High Sensitivity in Flow Cytometry, Western Blot, and immunohistochemistry
Biochem Biophys Rep, 41, 101948, https://doi.org/10.1016/j.bbrep.2025.101948, 2025 (PDF; preprint)
31.Ishikawa K, Suzuki H,Tanaka T,Kaneko MK, Kato Y.
Establishment of a high-affinity anti-mouse CXCR5 monoclonal antibody for flow cytometry
MI, 2(1), 101–113; https://doi.org/10.36922/mi.5664, 2025 (PDF; preprint)
30. Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Tanaka T, Kato Y.
A Humanized Cancer-Specific anti-HER2 Monoclonal Antibody, humH2Mab-250, Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Int. J. Mol. Sci., 2025(PDF; preprint)
29. Mishima Y, Okada S, Ishikawa A, Wang B, Waseda M, Kaneko MK, Kato Y, Kaneko S.
Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin
Regenerative Therapy, 28,292-300, https://doi.org/10.1016/j.reth.2024.12.010, 2025 (PDF)
2024
28. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
A Cancer-Specific anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerted Antitumor Activities in Human Tumor Xenograft Models
Cells, 13(22), 1833; https://doi.org/10.3390/cells13221833, 2024 (PDF; preprint)
27. Hirose M, Suzuki H, Ubukata R, Tanaka T, Kaneko MK, Kato Y.
Development of specific anti-mouse atypical chemokine receptor 4 monoclonal antibodies
Biochem Biophys Rep, 40, 101824, https://doi.org/10.1016/j.bbrep.2024.101824, 2024 (PDF; preprint)
26. Ishikawa K, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Li G, Tanaka T, Kawada M, Kaneko MK, Ohkoshi A, Katori Y, Kato Y.
Antitumor activities of defucosylated anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer
Oncology reports, 52(5), 147, https://doi.org/10.3892/or.2024.8806, (PDF; preprint)
25. Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, Ohkoshi A, Kaneko MK, Katori Y, Kato Y.
Anti-CD44 variant 10 monoclonal antibody exerts antitumor activity in mouse xenograft models of oral squamous cell carcinomas
Int. J. Mol. Sci., 25(17), 9190; https://doi.org/10.3390/ijms25179190, 2024 (PDF; preprint)
24. Ubukata R, Suzuki H, Tanaka T, Li G, Kaneko MK, Kato Y.
Development of Sensitive Anti-Mouse CCR5 Monoclonal Antibodies using the N-terminal peptide immunization
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 112-118, https://doi.org/10.1089/mab.2024.0009, 2024 (PDF)
23. Suzuki H, Tanaka T, Li G, Ouchida T, Kaneko MK, Kato Y.
Development of a Sensitive Anti-Mouse CCR5 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 96-100, https://doi.org/10.1089/mab.2024.0004, 2024 (PDF; preprint)
22. Kobayashi H, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Mouse CCR8 Monoclonal Antibody C8Mab-2 using flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 101-107, https://doi.org/10.1089/mab.2024.0002, 2024 (PDF; preprint)
21. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y.
Anti‐HER2 cancer‐specific mAb, H2Mab‐250‐hG1 possesses higher complement‐dependent cytotoxicity than trastuzumab
Int. J. Mol. Sci., 25(15), 8386; https://doi.org/10.3390/ijms25158386, 2024 (PDF; preprint)
20. Arimori T, Mihara E, Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Takagi J, Kato Y.
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Structure, 32(5),536-549, https://doi.org/10.1016/j.str.2024.02.007, 2024 (PDF)
19. Li G, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 59-66, DOI: 10.20944/preprints202311.0501.v2, 2023 (PDF;preprint)
18. Ouchida T, Li G, Suzuki H, Yanaka M, Nakamura T, Handa S, Tanaka T, Kaneko MK, Kato Y.
PMab-314: An Anti-Giant Panda Podoplanin Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 53-58, doi:10.1089/mab.2024.0003, 2024 (PDF)
17. Kaneko MK, Suzuki H, Kato Y.
Establishment of a novel cancer-specific anti-HER2 monoclonal antibody H2Mab-250/H2CasMab-2 for breast cancers
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 35-43,
DOI: 10.1089/mab.2023.0033, 2024 (PDF;online;preprint)
16. Ouchida T, Isoda Y, Nakamura T, Yanaka M, Tanaka T, Handa S, Kaneko MK, Suzuki H, Kato Y.
Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 67-74, https://doi.org/10.1089/mab.2023.0032, 2024 (PDF;preprint)
15. Okada Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 44-52, https://doi.org/10.1089/mab.2023.0029, 2024 (PDF;preprint)
14. Inoue T, Yamamoto Y, Sato K, Nakamura Y, Shimizu Y, Ogawa M, Onodera T, Takahashi Y, Wakita T, Kaneko MK, Fukasawa M, Kato Y, Noguchi K.
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
iScience,27(4),109363, DOI:https://doi.org/10.1016/j.isci.2024.109363, 2024 (PDF)
13. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Establishment of anti-dog PD-L1 monoclonal antibodies for immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 17–23, https://doi.org/10.1089/mab.2023.0014, 2024 (PDF; preprint)
12. Okada Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-Mouse CD39 Monoclonal Antibody (C39Mab-1) for Flow Cytometry and Western Blot Anal-yses
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 24–31, https://doi.org/10.1089/mab.2023.0016, 2024 (PDF; preprint)
11. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Cx4Mab-1: a Novel Anti-mouse CXCR4 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 10–16, DOI: 10.1089/mab.2023.0023, 2024 (PDF;preprint)
10. Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Tanaka T, Kato Y.
A Cancer-specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Int. J. Mol. Sci., 25(3), 1941; https://doi.org/10.3390/ijms25031941, 2024 (PDF)
9. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f
Cancer Sci., 115(1), 298-309, https://doi.org/10.1111/cas.16008, 2024 (PDF; preprint)
8. Suzuki H, Ohishi T, Tanaka T Kaneko MK, Kato Y.
A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts
Int. J. Mol. Sci., 25, 161. https://doi.org/10.3390/ijms25010161, 2024 (PDF; preprint)
2023
7. Isoda Y, Kaneko MK, Tanaka T, Suzuki H, Kato Y.
Epitope Mapping of an Anti-Ferret Podoplanin Monoclonal Antibody using the PA Tag-Substituted Analysis
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 189–193, DOI: 10.1089/mab.2023.0026, 2023 (PDF; preprint)
6. Ouchida T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
PMab-301: An Anti-Giraffe Podoplanin Monoclonal Antibody for Immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 209–215, https://doi.org/10.1089/mab.2023.0020, 2023 (PDF; preprint)
5. Suzuki H, Tanaka T, Kudo Y, Tawara M, Hirayama A, Kaneko MK, Kato Y.
A Rat Anti-Mouse CD39 Monoclonal Antibody for flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 203–208, DOI: 10.1089/mab.2023.0018, 2023 (PDF; preprint)
4. Nanamiya R, Suzuki H, Kaneko MK, Kato Y.
Development of an Anti−EphB4 Monoclonal Antibody for Multiple Applications against Breast Cancers
Monoclon. Antib. Immunodiagn. Immunother.,42(5), 153–156, https://doi.org/10.1089/mab.2023.0015, 2023 (PDF; preprint)
3. Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Humanized and defucosylated antibody against Podoplanin (humLpMab-23-f) exerted antitumor activities in human tumor xenograft models
Cancers, 15(20), 5080; https://doi.org/10.3390/cancers15205080, 2023 (PDF)
2. Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko MK, Kato Y.
Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2
Curr. Issues Mol. Biol., 45(10), 7734-7748; https://doi.org/10.3390/cimb45100488, 2023 (PDF)
1. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry
Int. J. Transl. Med., 3(3), 310-320; 2023 (PDF)
